US20100311829A1 - Novel Therapeutic Uses of Beta-3 Adrenergic Receptor Agonist Derivatives in Particular to Modulate Apoptosis - Google Patents
Novel Therapeutic Uses of Beta-3 Adrenergic Receptor Agonist Derivatives in Particular to Modulate Apoptosis Download PDFInfo
- Publication number
- US20100311829A1 US20100311829A1 US12/652,317 US65231710A US2010311829A1 US 20100311829 A1 US20100311829 A1 US 20100311829A1 US 65231710 A US65231710 A US 65231710A US 2010311829 A1 US2010311829 A1 US 2010311829A1
- Authority
- US
- United States
- Prior art keywords
- alkyl group
- group
- phenyl
- alkyl
- nhso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 42
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 title claims abstract description 14
- 230000001225 therapeutic effect Effects 0.000 title abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 208000035475 disorder Diseases 0.000 claims abstract description 21
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 45
- 150000001875 compounds Chemical class 0.000 claims description 32
- 206010060937 Amniotic cavity infection Diseases 0.000 claims description 25
- 208000008158 Chorioamnionitis Diseases 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 230000035935 pregnancy Effects 0.000 claims description 23
- 210000001519 tissue Anatomy 0.000 claims description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- -1 —CONR4R5 Chemical group 0.000 claims description 10
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 9
- 208000007313 Reproductive Tract Infections Diseases 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 5
- 208000030941 fetal growth restriction Diseases 0.000 claims description 5
- 208000012113 pregnancy disease Diseases 0.000 claims description 5
- 230000001568 sexual effect Effects 0.000 claims description 5
- 206010061452 Complication of pregnancy Diseases 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 208000021267 infertility disease Diseases 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 201000011461 pre-eclampsia Diseases 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 208000003107 Premature Rupture Fetal Membranes Diseases 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims 1
- 208000034615 apoptosis-related disease Diseases 0.000 abstract description 5
- 239000002158 endotoxin Substances 0.000 description 54
- 229920006008 lipopolysaccharide Polymers 0.000 description 54
- 102000003952 Caspase 3 Human genes 0.000 description 23
- 108090000397 Caspase 3 Proteins 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 21
- 230000002632 myometrial effect Effects 0.000 description 21
- 229940126062 Compound A Drugs 0.000 description 17
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 210000000754 myometrium Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000017918 ADRB3 Human genes 0.000 description 9
- 108060003355 ADRB3 Proteins 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 238000000540 analysis of variance Methods 0.000 description 7
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 7
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 7
- 210000002826 placenta Anatomy 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 0 *OCC(O)CNCC1CCC(CC2=CC=CC=C2)CC1.[3*]C Chemical compound *OCC(O)CNCC1CCC(CC2=CC=CC=C2)CC1.[3*]C 0.000 description 4
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 4
- 108050006685 Apoptosis regulator BAX Proteins 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
- 108091012583 BCL2 Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108700000707 bcl-2-Associated X Proteins 0.000 description 3
- 102000055102 bcl-2-Associated X Human genes 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 229940125712 tocolytic agent Drugs 0.000 description 3
- 239000003675 tocolytic agent Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000010867 Hoechst staining Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108091058560 IL8 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003822 cell turnover Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000002219 extraembryonic membrane Anatomy 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000009802 hysterectomy Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000025915 regulation of apoptotic process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000017919 ADRB2 Human genes 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 208000003384 Cephalopelvic Disproportion Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000032754 Infant Death Diseases 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical group NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043074 Tachycardia foetal Diseases 0.000 description 1
- 206010043391 Thalassaemia beta Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046827 Uterine tenderness Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000030 antiglaucoma agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- VEZDPEGPNPRTOH-PSLBYKFTSA-N chembl3184943 Chemical compound Cl.C1=CC(C(=O)OCC)=CC=C1[C@@H]1CC[C@@H](NC[C@H](O)COC=2C=C(NS(C)(=O)=O)C(O)=CC=2)CC1 VEZDPEGPNPRTOH-PSLBYKFTSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000006667 mitochondrial pathway Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003336 oxytocin antagonist Substances 0.000 description 1
- 229940121361 oxytocin antagonists Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000005152 placental membrane Anatomy 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003152 propanolamines Chemical group 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003195 tocolytic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to the novel therapeutic uses of beta-3 adrenergic receptor agonist derivatives in particular to modulate apoptosis.
- Beta-2-adrenergic receptor (ADRB2) agonists have long been used as tocolytic agents for the treatment of preterm labor, but, due to limited efficacy and toxicity, are no longer recommended as first choice drugs.
- Oxytocin antagonists and calcium channel blockers are more recently developed drugs with a lower profile of adverse affects, and hence more commonly used, even if calcium channel blockers, which were developed to treat hypertension, including in pregnant women, are not approved as tocolytic agents (Kim et al., Bjog 113 Suppl 3:113-115, 2006).
- ADRB3 is present, and is the predominant ADRB, in human myometrium (Bardou et al., Br J Pharmacol 130:1960-1966, 2000; Dennedy et al., Bjog 108:605-609, 2001; Rouget et al., J Clin Endocrinol Metab 90:1644-1650, 2005) with an inhibitory action on spontaneous contractions.
- Apoptosis is one of the main types of programmed cell death (PCD), and involves an orchestrated series of biochemical events leading to a characteristic cell morphology and death.
- PCD programmed cell death
- Research on apoptosis has increased substantially since the early 1990s.
- defective apoptotic processes have been implicated in an extensive variety of diseases.
- Cancer is a prime example of the crucial role of apoptotic regulation as defective anti-apoptotic effectors may result in uncontrolled cell proliferation.
- Apoptosis is also largely involved in uterine cell turnover and early pregnancy. It is well-documented that the rodent uterine epithelium around the embryo undergoes apoptosis in response to the presence of the blastocyst (Schlafke et al., Anat. Rec. 212:47-56, 1985; Parr et al., Biol. Reprod. 36:211-225, 1987; and Welsh et al., Am. J. Anat. 192:215-231, 1991). Joswig et al., Reproductive Biology and Endocrinology 1:44, 2003, proposed two different pathways for apoptosis in uterine epithelium and decidua in response to implantation.
- the first topic of interest for apoptosis in the field of pregnancy is the pathologies of the placenta. Indeed apoptosis of villous trophoblast is upregulated in both of the common pregnancy diseases related to the placenta, namely, intrauterine growth restriction (IUGR) and preeclampsia (Smith S C, et al. Am J Obstet Gynecol 1997; 177:1395-401; Allaire A D et al. Obstet Gynecol 2000; 96:271-6; Erel C T et al. Int J Gynaecol Obstet 2001; 73:229-35; Ishihara N, et al.
- IUGR intrauterine growth restriction
- Spontaneous preterm labor is one of the largest causes of preterm birth which in turn is the most frequent cause of infant death in the United States (Callaghan et al., Pediatrics 118, 1566-1573, 2006). Many cases of spontaneous preterm labor are unexplained but a significant proportion is linked to genital tract infection or chorioamnionitis (Edwards et al., Obstet. Gynecol. Clin. North Am. 32, 287-296, 2005).
- Apoptotic cell death can be initiated by two alternative convergent pathways: the extrinsic pathway, which is mediated by cell surface death receptors, and the intrinsic pathway, which is mediated by mitochondria (Danial et al., Cell 116:205-219, 2004).
- the extrinsic pathway which is mediated by cell surface death receptors
- the intrinsic pathway which is mediated by mitochondria
- cysteine aspartyl-specific proteases which cleave cellular substrates are activated
- activation of the effector caspase-3 is important for the execution of apoptotic cell death.
- the bcl2 family members play a central role in the regulation of apoptosis.
- WO02/44139 discloses that certain propanolamines bearing a cyclohexyl(alkyl) group on the amine possess a powerful agonist activity with respect to ADRB3.
- these compounds may be indicated in the treatment of gastrointestinal diseases such as inflammatory diseases of the intestine, for instance irritable bowel disease (IBD), as modulators of intestinal motivity, as lipolytic agents, anti-obesity agents, anti-diabetic agents, psychotropic agents, anti-glaucoma agents, cicatrizing agents and anti-depressants, as inhibitors of uterine contractions, as tocolytics for preventing or delaying preterm births, and for the treatment and/or prophylaxis of dysmenorrhoea.
- IBD irritable bowel disease
- these compounds could be used in the treatment of certain diseases of the central nervous system, such as for example depression, and also of certain disorders of the urinary system, such as urinary incontinence.
- ADRB3 plays a crucial role in controlling apoptotic pathways, in particular in pregnancy related tissues, namely uterus, placenta and fetal membranes. Additionally, it has also been surprisingly discovered that compounds disclosed in WO02/44139 are potent apoptosis inhibitors.
- the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament for preventing pregnancy related tissues apoptosis in female mammalian patients.
- the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament suitable to prevent and/or treat pregnancy related tissues apoptosis related diseases and/or disorders; more particularly to prevent and/or treat uterine apoptosis related diseases and/or disorders; more particularly to prevent and/or treat pregnancy related tissues apoptosis related diseases and/or disorders selected from sexual cycle disorders, fertility disorders and pregnancy disorders.
- the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament suitable to prevent and/or treat pregnancy related tissues apoptosis related diseases and/or disorders in female mammalian patients suffering from genital tract infection; more particularly to prevent and/or treat preterm labor in female mammalian patients suffering from genital tract infection; more particularly to prevent and/or treat preterm labor in female mammalian patients suffering from genital tract infection wherein genital tract infection is chorioamnionitis.
- the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament suitable to prevent and/or inhibit pregnancy related tissues apoptosis in pregnant women.
- the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament for preventing uterine apoptosis in women suffering from genital tract infection, with its consequences mainly preterm labor and preterm delivery.
- the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament suitable to prevent and/or treat fetal membranes apoptosis in women suffering from preterm premature rupture of fetal membranes.
- the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament suitable to prevent and/or treat placental apoptosis in women with pregnancy complicated by intrauterine growth restriction or preeclampsia.
- beta-3 adrenergic receptor agonist is selected from compounds of formula (I):
- A is a group of formula (a) or (b):
- R represents a hydrogen or halogen atom, an —S(O) z (C 1 -C 4 )alkyl group, an —NHSO 2 (C 1 -C 4 )alkyl group, an —SO 2 NH(C 1 -C 4 )alkyl group, an —NHSO 2 -phenyl-(C 1 -C 4 )alkyl group or an —NHSO 2 -phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C 1 -C 4 )alkyl group or with a (C 1 -C 4 )alkoxy group;
- R 1 represents a hydrogen atom or a (C 1 -C 4 )alkyl group, a —CO(C 1 -C 4 )alkyl group, a phenyl-(C 1 -C 4 )alkyl group or a —CO-phenyl group, said phenyl possibly being substituted with a halogen atom or with a (C 1 -C 4 )alkoxy group;
- R 2 is a hydrogen atom, an —SO 2 (C 1 -C 4 )alkyl group, an —SO 2 -phenyl-(C 1 -C 4 )alkyl group or an —SO 2 -phenyl group;
- X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C 1 -C 4 )alkyl groups and bearing one or two carbonyl groups;
- n, m and z are, independently, 0, 1 or 2;
- R3 represents a hydrogen or halogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 4 )alkoxy group, a —COO(C 1 -C 4 )alkyl group, a —CO(C 1 -C 4 )alkyl group, an —NHSO 2 (C 1 -C 4 )alkyl group, an —NHSO 2 -phenyl-(C 1 -C 4 )alkyl group, —NO 2 , —CN, —CONR 4 R 5 , —COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group;
- R 4 and R 5 represent, independently, a hydrogen atom, a phenyl, a (C 1 -C 4 )alkyl group or a phenyl-(C 1 -C 4 )alkyl group; or
- R 4 and R 5 with the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total;
- (C 1 -C 4 )alkyl and “(C 1 -C 6 )alkyl” denote monovalent radicals formed from a respectively C 1 -C 4 and C 1 -C 6 hydrocarbon containing a straight or branched saturated chain.
- halogen denotes an atom chosen from chlorine, bromine, iodine and fluorine.
- More particularly compounds are those in which n and m are each zero.
- More particularly compounds are those in which R 1 is a hydrogen atom.
- More particularly compounds are those in which R is chosen from an —NHSO 2 (C 1 -C 4 )alkyl group, an —NHSO 2 -phenyl-(C 1 -C 4 )alkyl group or an —NHSO 2 -phenyl group.
- R 3 is —COO(C 1 -C 4 )alkyl or —CO(C 1 -C 4 )alkyl or CONR 4 R 5 .
- More particularly compounds are those in which R 3 is in position 4 of the benzene.
- More particularly compounds are those in which z is 2.
- More particularly compounds are those in which X is a methylene, an ethylene or a propylene.
- More particularly compounds are those in which X is a carbonyl, a —CO—CO-group, a —CO—C((C 1 -C 4 )alkyl) 2 -CO— group, a methylene monosubstituted or disubstituted with (C 1 -C 4 )alkyl or a —COCH 2 — group.
- —NHSO 2 -phenyl-(C 1 -C 4 )alkyl and —SO 2 -phenyl-(C 1 -C 4 )alkyl groups are, respectively, benzylsulphonylamino and benzylsulphonyl.
- R 4 and R 5 form, with the nitrogen atom to which they are attached, a ring of 5 to 7 atoms, rings more particularly are piperidine and pyrrolidine.
- the salts of the compounds of formula (I) according to the present invention comprise both the addition salts with pharmaceutically acceptable inorganic or organic acids, such as hydrochlorate, hydrobromate, sulphate, hydrogen sulphate, dihydrogen phosphate, citrate, maleate, tartrate, fumarate, gluconate, methanesulphonate, 2-naphtalenesulphonate, etc., and the addition salts which allow suitable separation or crystallization of the compounds of formula (I), such as picrate or oxalate, or the addition salts with optically active acids, for example camphorsulphonic acids and mandelic or substituted mandelic acids.
- pharmaceutically acceptable inorganic or organic acids such as hydrochlorate, hydrobromate, sulphate, hydrogen sulphate, dihydrogen phosphate, citrate, maleate, tartrate, fumarate, gluconate, methanesulphonate, 2-naphtalenesulphonate, etc.
- the salts also comprise the salts with inorganic bases, preferably those with alkaline metals such as sodium or potassium, or with organic bases.
- optically pure stereoisomers and also the mixtures of isomers of the compounds of formula (I), due to the asymmetric carbon, in any proportion, are also part of the present invention.
- More particularly compounds of formula (I) are the compounds in which the configuration of the carbon of the propanolamine bearing the OH group is (S).
- the compounds of formula (I) may be in the form of “cis” or “trans” geometrical isomers, depending on the relative position of the substituents in positions 1 and 4 of the cyclohexyl ring (marked with a star). These pure isomers and their mixtures, in any proportion, are part of the present invention.
- the compounds of formula (I) are useful for the preparation of medicaments suitable to prevent and/or treat, in female patients in need thereof, diseases and/or disorders related to pregnancy related tissues apoptosis related, such as sexual cycle disorders, fertility disorders and pregnancy disorders, as well as preterm premature rupture of fetal membranes, as well as preterm labor, in particular preterm labor triggered by genital tract infection.
- diseases and/or disorders related to pregnancy related tissues apoptosis related such as sexual cycle disorders, fertility disorders and pregnancy disorders, as well as preterm premature rupture of fetal membranes, as well as preterm labor, in particular preterm labor triggered by genital tract infection.
- diseases and/or disorders related to pregnancy related tissues apoptosis related such as sexual cycle disorders, fertility disorders and pregnancy disorders, as well as preterm premature rupture of fetal membranes, as well as preterm labor, in particular preterm labor triggered by genital tract infection.
- preterm labor in particular preterm labor triggered by genital tract infection.
- female mammalian patients refers in particular to women.
- fertility disorders refers to disorders of the female fertility, in particular those associated with impaired uterine apoptosis, such as implantation as disclosed by Schlafke et al., Anat. Rec. 212:47-56, 1985; Parr et al., Biol. Reprod. 36:211-225, 1987; Welsh et al., Am. J. Anat. 192:215-231, 1991 and Joswig et al., Reproductive Biology and Endocrinology 1:44, 2003.
- pregnancy disorders refers to disorders of the pregnancy in female mammalian, in particular those associated with impaired uterine apoptosis, such as early pregnancy as as disclosed by Schlafke et al., Anat. Rec. 212:47-56, 1985; Parr et al., Biol. Reprod. 36:211-225, 1987; Welsh et al., Am. J. Anat. 192:215-231, 1991 and Joswig et al., Reproductive Biology and Endocrinology 1:44, 2003.
- an effective amount of a compound of formula (I), or of a pharmaceutically acceptable salt thereof, is administered to the mammals which require such a treatment.
- the compounds of formula (I) above, and the pharmaceutically acceptable salts thereof, may be used at daily doses of 0.01 to 20 mg per kilo of body weight of the mammal to be treated, preferably at daily doses of from 0.1 to 10 mg/kg.
- the dose may vary preferably from 0.5 mg to 1500 mg per day, in particular from 2.5 to 500 mg, depending on the age of the individual to be treated, the type of treatment, prophylactic or curative, and the seriousness of the disorder.
- the compounds of formula (I) are generally administered as a dosage unit of 0.1 to 500 mg, preferably of 0.5 to 100 mg, of active principle, one to five times a day.
- Said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed with a pharmaceutical excipient.
- the present invention relates to pharmaceutical compositions containing, as an active principle, a compound of formula (I) above or a pharmaceutically acceptable salt thereof.
- the active ingredients of formula (I) above, and the pharmaceutically acceptable salts thereof may be administered in unit administration forms, mixed with conventional pharmaceutical supports, to animals and humans for treating the abovementioned disorders.
- the unit administration forms which are suitable comprise oral forms such as tablets, gel capsules, powders, granules and oral solutions or suspensions, sublingual and buccal administration forms, subcutaneous, intramuscular or intravenous administration forms, local administration forms and rectal administration forms.
- the main active ingredient is mixed with a pharmaceutical vehicle such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
- a pharmaceutical vehicle such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
- the tablets may be coated with sucrose or other suitable materials, or they may be treated such that they have sustained or delayed activity and that they release, in a continuous manner, a predetermined amount of active principle.
- a preparation of gel capsules is obtained by mixing the active ingredient with a diluent and pouring the mixture obtained into soft or hard gel capsules.
- a preparation in the form of a syrup or elixir may contain the active ingredient together with a sweetener, preferably a calorie-free sweetener, methylparaben and propylparaben as antiseptics, and also a flavour enhancer and a suitable colorant.
- a sweetener preferably a calorie-free sweetener, methylparaben and propylparaben as antiseptics, and also a flavour enhancer and a suitable colorant.
- the water-dispersible powders or granules may contain the active ingredient mixed with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone, and also with sweeteners or flavour correctors.
- the active principle is mixed into an excipient for preparing creams or ointments, or it is dissolved in a vehicle for intraocular administration, for example in the form of an eyewash.
- suppositories prepared with binders which melt at rectal temperature, for example cocoa butter or polyethylene glycols.
- aqueous suspensions, saline solutions or injectable sterile solutions which contain pharmacologically compatible dispersion agents and/or wetting agents, for example propylene glycol or butylene glycol, are used.
- the active principle may also be formulated in the form of microcapsules, optionally with one or more supports or additives.
- FIG. 1 represents Western Blot Analysis with semi-quantification showing the expression of cleaved caspase-3 protein.
- CA group myometrial samples obtained from 3 different women with Chorioamnionitis (CA group), and with 5 myometrium, obtained at cesarean delivery from 5 different women with uncomplicated pregnancies and stimulated, or not, with LPS (LPS and CTRL groups respectively). *P ⁇ 0.05 vs. controls.
- FIG. 2 illustrates Western Blot Analysis with semi-quantification showing the expression of cleaved caspase-3 protein.
- FIG. 3 illustrates Western Blot Analysis with semi-quantification showing the expression of cleaved caspase-3 protein.
- FIG. 4 illustrates Western Blot Analysis with semi-quantification showing the expression of BAX and Bcl-2 protein.
- FIG. 5 show the effect of Compound A on the concentrations of IL-6 and IL-8.
- Results (mean ⁇ s.e.m, in pg/ml) are from five experiments performed in duplicate in myometrium, obtained at elective cesarean delivery, from five different women. #P ⁇ 0.05 vs controls, *P ⁇ 0.05 vs LPS, **P ⁇ 0.01 vs LPS.
- Lipopolysaccharide ( Escherichia coli 055:B5, ref: L2880) was purchased from Sigma-Aldrich and was dissolved in distilled water.
- Compound A was a gift from Sanofi-Midy Research Center, Exploratory Research Department, Sanofi-Aventis S.p.A. It was dissolved in a mixture of absolute ethanol 30%, dimethylsulfoxide 2%, and distilled water for the 1 mM solution and thereafter diluted in distilled water. The final maximal bath concentration was 0.3% for ethanol and 0.02% for DMSO.
- Myometrial biopsies were obtained from women during pregnancy in four different clinical situations as outlined: i) a woman with established chorioamnionitis undergoing postpartum hysterectomy; ii) a woman undergoing postpartum hysterectomy for postpartum hemorrhage in the absence of chorioamnionitis; iii) 3 women undergoing elective caesarean section with established chorioamnionitis; iv) 10 women undergoing elective caesarean section for other reasons (cephalo-pelvic disproportion) in the absence of chorioamnionitis.
- chorioamnionitis refers to confirmed chorioamnionitis.
- Myometrial strips were excised from an immediately subserosal site where the majority of the fibers are in a longitudinal orientation, at an antiplacental site, as previously described (Rouget C, et al. J Clin Endocrinol Metab 2005; 90: 1644-1650, Leroy M J, et al. Biochem Pharmacol 1989; 38: 9-15). This study was approved by the “Comitati Consultatif de Protection des Personnes pour la mecanic Biometriccale” (CCPPRB, Dijon, France) and informed consent was obtained from all donors.
- Tissues obtained from women with confirmed chorioamnionitis or postpartum hemorrhage were either used fresh to perform western blot experiments, or embedded in paraffin for histological assessment and Hoechst staining, as described below.
- Myometrial biopsies obtained from uncomplicated pregnancies were used to develop the LPS experimental model mimicking the effects of chorioamnionitis.
- the supernatants samples and tissues were quickly frozen in liquid nitrogen and stored at ⁇ 80° C.
- Proteins were transferred to a nitrocellulose membrane (Hybond-P, Amersham Biosciences).
- a nitrocellulose membrane Hybond-P, Amersham Biosciences.
- membranes were incubated for 1 h in 10% nonfat dried milk powder in Tris-buffered saline/Tween 20 (TBST) (10 mM Tris, 150 mM NaCl, and 0.1% Tween 20, pH 7.8) at room temperature. Blocked membranes were washed 3 times with TBST. The blots were then incubated overnight at 4° C.
- TST Tris-buffered saline/Tween 20
- the intensities of the bands were analyzed densitometrically using the NIH Image 1.62 program and normalized with intensity of bands obtained with monoclonal antibody to Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH) used as protein loading control. Results are expressed as the mean ⁇ s.e.m. in Arbitrary Density Unit (A.D.U).
- the myometrial strips were fixed for 1 h with paraformaldehyde 4%, then embedded in paraffin and cut into 5-micrometer-thick sections.
- antigen retrieval was performed by incubating slides 10 min in warm citric acid buffer pH 6 with a pressure cooker. After endogenous peroxidase activity was blocked with hydrogen peroxide (H 2 O 2 ) 3%, slides were incubated either with primary anti-cleaved caspase-3 IgG (1:100), washed three times with phosphate buffered saline (PBS) and then incubated with biotinylated anti-rabbit (1:600) immunoglobulin respectively for 1 h.
- PBS phosphate buffered saline
- chromatin condensation state was assessed by staining of nuclei with Hoechst-33342. Paraffin embedded sections of myometrium samples were re-hydrated as described above. Slides were then incubated for 2 min with Hoechst-33342 (2 ⁇ g/ml). The slides were rinsed with distilled water and mounted with Aquatex ⁇ . The stained nuclei were visualized with convert fluorescent microscope at a magnification of ⁇ 100, using excitation light at 350 nm.
- PCR analyses were performed using 25 ng of reverse transcribed total RNA with 200 nM of both sense and anti sense primers in a final volume of 25 ⁇ l using the SYBR Green PCR jumpstart reagent (Sigma, Saint Louis, Mo., USA) in an iCycler iQ real time detection system instrument (Bio-Rad, Marnes-1a-Coquette, France). PCR products were also analyzed on edithium bromide stained agarose gel to ensure that a single amplicon of the expected size was indeed obtained.
- Glyceraldehyde-3-phosphate dehydrogenase Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used in each experiment to control for variability in the quantities of cDNA.
- ⁇ Ct Ct of the experimental group—Ct of the control group.
- PCR was performed using specific primers: GAPDH (Forward, 5′TGCACCACCAACTGCTTAGC3′ (SEQ ID NO:1), and Reverse, 5′GGCATGGACTGTGGTC-ATGAG3′ (SEQ ID NO:2)) and CASPASE-3 (Forward, 5′ AGAACTGGACTGTGGCATTGAG 3′ (SEQ ID NO:3), and Reverse, 5′ GCTTGTCGGCATACTGTTTCAG 3′ (SEQ ID NO:4)).
- Cytokines measurements were determined by Cytometric Bead Array (CBA; Bender MedSystems). Supernatants of 5 myometrial strips were incubated with labeled capture beads and detection reagent for 3 h in the dark at room temperature, and analyzed with a flow cytometer (FACSCalibur; BD Biosciences) by using the respective CBA Analysis software (BD Biosciences) and Bender MedSystems software. Cytokine standards for quantification (pg/mL) as well as the blanks were handled in the same manner as the samples. Each experiment was performed in duplicate to ensure for reproducibility of results.
- CBA Cytometric Bead Array
- LPS stimulation in optimal conditions i.e 10 ⁇ g/ml for 48 h, determined after time course—8 h, 24 h, 48 h—and dose response—50 ng/ml, 1 ⁇ g/ml, 10 ⁇ g/ml—experiments of LPS stimulation
- dose response 50 ng/ml, 1 ⁇ g/ml, 10 ⁇ g/ml—experiments of LPS stimulation
- the solvent for the highest concentration of Compound A i.e. distilled water containing ethanol 0.3% and DMSO 0.02%, had no effect on cleaved caspase-3, BAX and BCL2 expression in tissues either not stimulated or stimulated with LPS (data not shown).
- a unitary dosage form of a compound of the invention in the form of a tablet may comprise the following constituents:
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- The present invention relates to the novel therapeutic uses of beta-3 adrenergic receptor agonist derivatives in particular to modulate apoptosis.
- Beta-2-adrenergic receptor (ADRB2) agonists have long been used as tocolytic agents for the treatment of preterm labor, but, due to limited efficacy and toxicity, are no longer recommended as first choice drugs. Oxytocin antagonists and calcium channel blockers are more recently developed drugs with a lower profile of adverse affects, and hence more commonly used, even if calcium channel blockers, which were developed to treat hypertension, including in pregnant women, are not approved as tocolytic agents (Kim et al., Bjog 113 Suppl 3:113-115, 2006). It has recently been shown that ADRB3 is present, and is the predominant ADRB, in human myometrium (Bardou et al., Br J Pharmacol 130:1960-1966, 2000; Dennedy et al., Bjog 108:605-609, 2001; Rouget et al., J Clin Endocrinol Metab 90:1644-1650, 2005) with an inhibitory action on spontaneous contractions.
- Apoptosis is one of the main types of programmed cell death (PCD), and involves an orchestrated series of biochemical events leading to a characteristic cell morphology and death. Research on apoptosis has increased substantially since the early 1990s. In addition to its importance as a biological phenomenon, defective apoptotic processes have been implicated in an extensive variety of diseases. Cancer is a prime example of the crucial role of apoptotic regulation as defective anti-apoptotic effectors may result in uncontrolled cell proliferation.
- The review by Solary et al., Eur. Respir. J. 9, 1293-1305, 1996 confirms the role of apoptosis in cancers; viral infections; autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis, autoimmune diabetes mellitus, inflammatory bowel syndrome, type 1 diabetes mellitus; fas-mediated disease such as fulminent hepatitis, CTL-mediated autoimmune disease including chronic thyroiditis; AIDS; haematological diseases such as myelodisplastic syndromes, aplastic anaemia, chronic neutropenia, severe beta-thalassaemia; neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, cerebellar degeneration, retinal pigmentosa, spinal muscular atrophy; and other various diseases including polycystic kidney disease, toxic-induced liver diseases, ischaemic injury, such as myocardial infarction or stroke, atheroma, arthritis, osteoporosis and ageing.
- Apoptosis is also largely involved in uterine cell turnover and early pregnancy. It is well-documented that the rodent uterine epithelium around the embryo undergoes apoptosis in response to the presence of the blastocyst (Schlafke et al., Anat. Rec. 212:47-56, 1985; Parr et al., Biol. Reprod. 36:211-225, 1987; and Welsh et al., Am. J. Anat. 192:215-231, 1991). Joswig et al., Reproductive Biology and Endocrinology 1:44, 2003, proposed two different pathways for apoptosis in uterine epithelium and decidua in response to implantation. More recently, Qian Zhang et al., Endocrinology 147(5), 2215-2227, 2006, studied apoptosis and proliferation in uterine cell turnover during the estrous cycle and early pregnancy. Their results indicate that uterine cell apoptosis and proliferation patterns are highly ordered cell-specific phenomena that play an important role in maintaining the sexual cycle and pregnancy-associated uterine changes. In particular, they indicate that caspase-3-mediated cell apoptosis may play an important role in initiating the implantation process in hamsters and mice.
- The first topic of interest for apoptosis in the field of pregnancy is the pathologies of the placenta. Indeed apoptosis of villous trophoblast is upregulated in both of the common pregnancy diseases related to the placenta, namely, intrauterine growth restriction (IUGR) and preeclampsia (Smith S C, et al. Am J Obstet Gynecol 1997; 177:1395-401; Allaire A D et al. Obstet Gynecol 2000; 96:271-6; Erel C T et al. Int J Gynaecol Obstet 2001; 73:229-35; Ishihara N, et al. Am J Obstet Gynecol 2002; 186:158-66.). Since it has recently been shown that apoptotic nuclei are more abundant in fetal growth restricted placentas compared with control placentas (Madazli R, et al. J Obstet Gynaecol 2006; 26:5-10) inhibiting apoptosis can be considered as promising approach to treat or prevent IUGR or preeclampsia.
- Spontaneous preterm labor, whether explained or unexplained, is one of the largest causes of preterm birth which in turn is the most frequent cause of infant death in the United States (Callaghan et al., Pediatrics 118, 1566-1573, 2006). Many cases of spontaneous preterm labor are unexplained but a significant proportion is linked to genital tract infection or chorioamnionitis (Edwards et al., Obstet. Gynecol. Clin. North Am. 32, 287-296, 2005).
- Charpigny et al., Biol. Reprod., 68, 2289-2296, 2003, showed that apoptosis associated genes were up-regulated during parturition.
- Apoptotic cell death can be initiated by two alternative convergent pathways: the extrinsic pathway, which is mediated by cell surface death receptors, and the intrinsic pathway, which is mediated by mitochondria (Danial et al., Cell 116:205-219, 2004). In both pathways, cysteine aspartyl-specific proteases (caspases) which cleave cellular substrates are activated, and activation of the effector caspase-3 is important for the execution of apoptotic cell death. The bcl2 family members play a central role in the regulation of apoptosis. The multidomain proapoptotic proteins Bax and Bak together constitute a requisite gateway to apoptotic cell death because cells doubly deficient for these proteins are resistant to several different intrinsic death stimuli (Danial et al., Cell 116:205-219, 2004). Therefore BAX, Bcl-2 and cleaved caspase-3 are widely used to assess apoptosis.
- WO02/44139 discloses that certain propanolamines bearing a cyclohexyl(alkyl) group on the amine possess a powerful agonist activity with respect to ADRB3. This document suggests that these compounds may be indicated in the treatment of gastrointestinal diseases such as inflammatory diseases of the intestine, for instance irritable bowel disease (IBD), as modulators of intestinal motivity, as lipolytic agents, anti-obesity agents, anti-diabetic agents, psychotropic agents, anti-glaucoma agents, cicatrizing agents and anti-depressants, as inhibitors of uterine contractions, as tocolytics for preventing or delaying preterm births, and for the treatment and/or prophylaxis of dysmenorrhoea. In addition, these compounds could be used in the treatment of certain diseases of the central nervous system, such as for example depression, and also of certain disorders of the urinary system, such as urinary incontinence.
- Nevertheless, the use of these compounds for preventing and/or inhibiting apoptosis is neither disclosed nor suggested. More generally the nexus between ADRB3 and apoptosis has not been established or suggested so far.
- There is therefore a need to identify new biological targets for controlling apoptosis and modulators thereof.
- The present inventors have now found, and that is an object of the present invention, that ADRB3 plays a crucial role in controlling apoptotic pathways, in particular in pregnancy related tissues, namely uterus, placenta and fetal membranes. Additionally, it has also been surprisingly discovered that compounds disclosed in WO02/44139 are potent apoptosis inhibitors.
- According to a first object, the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament for preventing pregnancy related tissues apoptosis in female mammalian patients.
- According to another object, the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament suitable to prevent and/or treat pregnancy related tissues apoptosis related diseases and/or disorders; more particularly to prevent and/or treat uterine apoptosis related diseases and/or disorders; more particularly to prevent and/or treat pregnancy related tissues apoptosis related diseases and/or disorders selected from sexual cycle disorders, fertility disorders and pregnancy disorders.
- According to another object, the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament suitable to prevent and/or treat pregnancy related tissues apoptosis related diseases and/or disorders in female mammalian patients suffering from genital tract infection; more particularly to prevent and/or treat preterm labor in female mammalian patients suffering from genital tract infection; more particularly to prevent and/or treat preterm labor in female mammalian patients suffering from genital tract infection wherein genital tract infection is chorioamnionitis.
- According to another object, the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament suitable to prevent and/or inhibit pregnancy related tissues apoptosis in pregnant women.
- According to another object, the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament for preventing uterine apoptosis in women suffering from genital tract infection, with its consequences mainly preterm labor and preterm delivery.
- According to another object, the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament suitable to prevent and/or treat fetal membranes apoptosis in women suffering from preterm premature rupture of fetal membranes.
- According to another object, the present invention concerns the use of a beta-3 adrenergic receptor agonist for the preparation of a medicament suitable to prevent and/or treat placental apoptosis in women with pregnancy complicated by intrauterine growth restriction or preeclampsia.
- According to another object, said beta-3 adrenergic receptor agonist is selected from compounds of formula (I):
- where in formula (I):
- A is a group of formula (a) or (b):
- where:
- R represents a hydrogen or halogen atom, an —S(O)z(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —SO2NH(C1-C4)alkyl group, an —NHSO2-phenyl-(C1-C4)alkyl group or an —NHSO2-phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C1-C4)alkyl group or with a (C1-C4)alkoxy group;
- R1 represents a hydrogen atom or a (C1-C4)alkyl group, a —CO(C1-C4)alkyl group, a phenyl-(C1-C4)alkyl group or a —CO-phenyl group, said phenyl possibly being substituted with a halogen atom or with a (C1-C4)alkoxy group;
- R2 is a hydrogen atom, an —SO2(C1-C4)alkyl group, an —SO2-phenyl-(C1-C4)alkyl group or an —SO2-phenyl group;
- X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C1-C4)alkyl groups and bearing one or two carbonyl groups;
- n, m and z are, independently, 0, 1 or 2;
- R3 represents a hydrogen or halogen atom, a (C1-C6)alkyl group, a (C1-C4)alkoxy group, a —COO(C1-C4)alkyl group, a —CO(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —NHSO2-phenyl-(C1-C4)alkyl group, —NO2, —CN, —CONR4R5, —COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group;
- R4 and R5 represent, independently, a hydrogen atom, a phenyl, a (C1-C4)alkyl group or a phenyl-(C1-C4)alkyl group; or
- R4 and R5 with the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total;
- and the salts thereof.
- In the present description, the terms “(C1-C4)alkyl” and “(C1-C6)alkyl” denote monovalent radicals formed from a respectively C1-C4 and C1-C6 hydrocarbon containing a straight or branched saturated chain.
- In the present description, the term “halogen” denotes an atom chosen from chlorine, bromine, iodine and fluorine.
- More particularly compounds are those in which n and m are each zero.
- More particularly compounds are those in which R1 is a hydrogen atom.
- More particularly compounds are those in which R is chosen from an —NHSO2(C1-C4)alkyl group, an —NHSO2-phenyl-(C1-C4)alkyl group or an —NHSO2-phenyl group.
- More particularly compounds are those in which R3 is —COO(C1-C4)alkyl or —CO(C1-C4)alkyl or CONR4R5.
- More particularly compounds are those in which R3 is in position 4 of the benzene.
- More particularly compounds are those in which z is 2.
- More particularly compounds are those in which X is a methylene, an ethylene or a propylene.
- More particularly compounds are those in which X is a carbonyl, a —CO—CO-group, a —CO—C((C1-C4)alkyl)2-CO— group, a methylene monosubstituted or disubstituted with (C1-C4)alkyl or a —COCH2— group.
- More particularly —NHSO2-phenyl-(C1-C4)alkyl and —SO2-phenyl-(C1-C4)alkyl groups are, respectively, benzylsulphonylamino and benzylsulphonyl.
- When R4 and R5 form, with the nitrogen atom to which they are attached, a ring of 5 to 7 atoms, rings more particularly are piperidine and pyrrolidine.
- The following compound is particularly advantageous:
- Ethyl-4-{trans-4-[((2S)-2-hydroxy-3-{4-hydroxy-3[(methylsulfonyl)-amino]phenoxy}propyl)amino]cyclohexyl}benzoate hydrochloride, herein called Compound A; it is a compound of formula (I) as disclosed above where A is a group of formula (a) where R is —NHSO2-Methyle, R1 is OH, n=m=0 and R3 is —COOEthyle.
- The salts of the compounds of formula (I) according to the present invention comprise both the addition salts with pharmaceutically acceptable inorganic or organic acids, such as hydrochlorate, hydrobromate, sulphate, hydrogen sulphate, dihydrogen phosphate, citrate, maleate, tartrate, fumarate, gluconate, methanesulphonate, 2-naphtalenesulphonate, etc., and the addition salts which allow suitable separation or crystallization of the compounds of formula (I), such as picrate or oxalate, or the addition salts with optically active acids, for example camphorsulphonic acids and mandelic or substituted mandelic acids.
- When the compounds of formula (I) have a free carboxyl group, the salts also comprise the salts with inorganic bases, preferably those with alkaline metals such as sodium or potassium, or with organic bases.
- The optically pure stereoisomers, and also the mixtures of isomers of the compounds of formula (I), due to the asymmetric carbon, in any proportion, are also part of the present invention.
- More particularly compounds of formula (I) are the compounds in which the configuration of the carbon of the propanolamine bearing the OH group is (S).
- The compounds of formula (I) may be in the form of “cis” or “trans” geometrical isomers, depending on the relative position of the substituents in positions 1 and 4 of the cyclohexyl ring (marked with a star). These pure isomers and their mixtures, in any proportion, are part of the present invention.
- The mixtures of optical and geometrical stereoisomers above, in any proportion, are also part of the present invention.
- The process of preparation of the compounds of formula (I) is disclosed in WO 02/44139.
- The compounds of formula (I) are useful for the preparation of medicaments suitable to prevent and/or treat, in female patients in need thereof, diseases and/or disorders related to pregnancy related tissues apoptosis related, such as sexual cycle disorders, fertility disorders and pregnancy disorders, as well as preterm premature rupture of fetal membranes, as well as preterm labor, in particular preterm labor triggered by genital tract infection. Such patients can be readily identified by the routine analysis.
- The expression “female mammalian patients” used herein refers in particular to women.
- The expression “sexual cycle disorders” used herein refers to disorders of the female menstrual cycle, in particular those associated with impaired uterine apoptosis, as suggested by Qian Zhang et al., Endocrinology 147(5), 2215-2227, 2006
- The expression “fertility disorders” used herein refers to disorders of the female fertility, in particular those associated with impaired uterine apoptosis, such as implantation as disclosed by Schlafke et al., Anat. Rec. 212:47-56, 1985; Parr et al., Biol. Reprod. 36:211-225, 1987; Welsh et al., Am. J. Anat. 192:215-231, 1991 and Joswig et al., Reproductive Biology and Endocrinology 1:44, 2003.
- The expression “pregnancy disorders” used herein refers to disorders of the pregnancy in female mammalian, in particular those associated with impaired uterine apoptosis, such as early pregnancy as as disclosed by Schlafke et al., Anat. Rec. 212:47-56, 1985; Parr et al., Biol. Reprod. 36:211-225, 1987; Welsh et al., Am. J. Anat. 192:215-231, 1991 and Joswig et al., Reproductive Biology and Endocrinology 1:44, 2003.
- For the uses of the invention, an effective amount of a compound of formula (I), or of a pharmaceutically acceptable salt thereof, is administered to the mammals which require such a treatment.
- The compounds of formula (I) above, and the pharmaceutically acceptable salts thereof, may be used at daily doses of 0.01 to 20 mg per kilo of body weight of the mammal to be treated, preferably at daily doses of from 0.1 to 10 mg/kg. In humans, the dose may vary preferably from 0.5 mg to 1500 mg per day, in particular from 2.5 to 500 mg, depending on the age of the individual to be treated, the type of treatment, prophylactic or curative, and the seriousness of the disorder. The compounds of formula (I) are generally administered as a dosage unit of 0.1 to 500 mg, preferably of 0.5 to 100 mg, of active principle, one to five times a day.
- Said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed with a pharmaceutical excipient.
- Thus, according to another of its aspects, the present invention relates to pharmaceutical compositions containing, as an active principle, a compound of formula (I) above or a pharmaceutically acceptable salt thereof.
- In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, transdermal or rectal administration, the active ingredients of formula (I) above, and the pharmaceutically acceptable salts thereof, may be administered in unit administration forms, mixed with conventional pharmaceutical supports, to animals and humans for treating the abovementioned disorders. The unit administration forms which are suitable comprise oral forms such as tablets, gel capsules, powders, granules and oral solutions or suspensions, sublingual and buccal administration forms, subcutaneous, intramuscular or intravenous administration forms, local administration forms and rectal administration forms.
- When a solid composition in the form of tablets is prepared, the main active ingredient is mixed with a pharmaceutical vehicle such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like. The tablets may be coated with sucrose or other suitable materials, or they may be treated such that they have sustained or delayed activity and that they release, in a continuous manner, a predetermined amount of active principle.
- A preparation of gel capsules is obtained by mixing the active ingredient with a diluent and pouring the mixture obtained into soft or hard gel capsules.
- A preparation in the form of a syrup or elixir may contain the active ingredient together with a sweetener, preferably a calorie-free sweetener, methylparaben and propylparaben as antiseptics, and also a flavour enhancer and a suitable colorant.
- The water-dispersible powders or granules may contain the active ingredient mixed with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone, and also with sweeteners or flavour correctors.
- For local administration, the active principle is mixed into an excipient for preparing creams or ointments, or it is dissolved in a vehicle for intraocular administration, for example in the form of an eyewash.
- For rectal administration, use is made of suppositories prepared with binders which melt at rectal temperature, for example cocoa butter or polyethylene glycols.
- For parenteral administration, aqueous suspensions, saline solutions or injectable sterile solutions which contain pharmacologically compatible dispersion agents and/or wetting agents, for example propylene glycol or butylene glycol, are used.
- The active principle may also be formulated in the form of microcapsules, optionally with one or more supports or additives.
-
FIG. 1 represents Western Blot Analysis with semi-quantification showing the expression of cleaved caspase-3 protein. CTRL=control; LPS=10 μg/ml LPS, 48 h; CA=Chorioamnionitis. Experiments were performed in myometrial samples obtained from 3 different women with Chorioamnionitis (CA group), and with 5 myometrium, obtained at cesarean delivery from 5 different women with uncomplicated pregnancies and stimulated, or not, with LPS (LPS and CTRL groups respectively). *P<0.05 vs. controls. -
FIG. 2 illustrates Western Blot Analysis with semi-quantification showing the expression of cleaved caspase-3 protein. Controls=time-matched experiments; LPS=10 μg/ml LPS 48 h, TNFα-ab=10 μg/ml LPS+0.6 μg/ml TNFα-ab, 48 h. Experiments were performed on three myometrium obtained at elective cesarean delivery from three different women. *P<0.05 vs. LPS. -
FIG. 3 illustrates Western Blot Analysis with semi-quantification showing the expression of cleaved caspase-3 protein. Controls=time-matched experiments; LPS=10 μg/ml LPS 48 h. Compound A (10−7M, 10−6M, 10−5M) was added 20 min. prior to LPS stimulation. Experiments were performed on five myometrium, obtained at elective cesarean delivery from five different women. #P<0.05 vs controls, *P<0.05 vs. LPS. -
FIG. 4 illustrates Western Blot Analysis with semi-quantification showing the expression of BAX and Bcl-2 protein. Controls=time-matched experiments; LPS=10 μg/ml LPS 48 h. Compound A (10−7M, 10−6M, 10−5M) was added 20 min. prior to LPS stimulation. Experiments were performed on seven myometrium, obtained at elective cesarean delivery, from seven different women. #P<0.05 vs controls, *P<0.05 vs. LPS, **P<0.01 vs LPS. -
FIG. 5 show the effect of Compound A on the concentrations of IL-6 and IL-8. Results (mean±s.e.m, in pg/ml) are from five experiments performed in duplicate in myometrium, obtained at elective cesarean delivery, from five different women. #P<0.05 vs controls, *P<0.05 vs LPS, **P<0.01 vs LPS. - The following examples further illustrate the present invention:
- Lipopolysaccharide (LPS) (Escherichia coli 055:B5, ref: L2880) was purchased from Sigma-Aldrich and was dissolved in distilled water. Compound A was a gift from Sanofi-Midy Research Center, Exploratory Research Department, Sanofi-Aventis S.p.A. It was dissolved in a mixture of absolute ethanol 30%, dimethylsulfoxide 2%, and distilled water for the 1 mM solution and thereafter diluted in distilled water. The final maximal bath concentration was 0.3% for ethanol and 0.02% for DMSO.
- Biological Samples
- Myometrial biopsies were obtained from women during pregnancy in four different clinical situations as outlined: i) a woman with established chorioamnionitis undergoing postpartum hysterectomy; ii) a woman undergoing postpartum hysterectomy for postpartum hemorrhage in the absence of chorioamnionitis; iii) 3 women undergoing elective caesarean section with established chorioamnionitis; iv) 10 women undergoing elective caesarean section for other reasons (cephalo-pelvic disproportion) in the absence of chorioamnionitis. For women undergoing caesarean section, the procedures were all performed prior to the onset of labor at a gestation period between 38 and 40 weeks of pregnancy. Clinical chorioamnionitis was defined classically (Redline R W et al. Placenta 2005; 26 Suppl A: S114-117) as the presence of uterine tenderness and/or purulent or foul-smelling amniotic fluid with any 2 of the following: antepartum temperature of 37.8° C. or more, maternal tachycardia (more than 120 beats/min), maternal leukocytosis more than 18,000 cells/mm3, or fetal tachycardia (more than 160 beats/min) and was confirmed, in all cases included in the present study, by either a positive culture of the placenta or an histological assessment of the placenta by a single pathologist using validated criteria (Redline R W et al. Pediatr Dev Pathol 2003; 6: 435-448). Therefore in the rest of this study chorioamnionitis refers to confirmed chorioamnionitis.
- Myometrial strips were excised from an immediately subserosal site where the majority of the fibers are in a longitudinal orientation, at an antiplacental site, as previously described (Rouget C, et al. J Clin Endocrinol Metab 2005; 90: 1644-1650, Leroy M J, et al. Biochem Pharmacol 1989; 38: 9-15). This study was approved by the “Comité Consultatif de Protection des Personnes pour la Recherche Biomédicale” (CCPPRB, Dijon, France) and informed consent was obtained from all donors.
Tissues obtained from women with confirmed chorioamnionitis or postpartum hemorrhage, were either used fresh to perform western blot experiments, or embedded in paraffin for histological assessment and Hoechst staining, as described below.
Myometrial biopsies obtained from uncomplicated pregnancies were used to develop the LPS experimental model mimicking the effects of chorioamnionitis. - Stimulation of Myometrial Biopsies by E. Coli LPS
- Myometrial biopsies obtained from women with uncomplicated pregnancies were immediately transferred in sterile Dubelcco's Modified Eagle Medium (DMEM) and washed twice with sterile Phosphate Buffer Saline (PBS). Biopsies were cut into small strips, each being placed in a 24-well plate containing 2 ml of culture medium DMEM, without the use of antibiotics. Strips were then incubated at 37° C. with 5% CO2 for 48 h in order to allow cytokine levels to return to basal values (Fortunato S J, et al. Am J Reprod Immunol 1994; 32: 184-187).
- In order to reproduce with LPS (Escherichia coli 055:B5) the findings on myometrial samples obtained from women with chorioamnionitis, myometrial strips were incubated with three different concentrations of LPS (50 ng/ml, 1 μg/ml and 10 μg/ml) at three different times (8 h, 24 h, 48 h).
In a second set of experiments, in order to assess the role of TNF in LPS-induced apoptosis in myometrial tissue, the strips were incubated with LPS 10 μg/ml for 48 h with or without anti TNF antibodies (0.6 μg/ml) (Human TNF alpha/TNFSF1A antibody, R&D systems Europe, Lille, France, the concentration of the antibody used was chosen based on the manufacturer's recommendations).
In a third set of experiments aimed to assess the ability of ADRB3 stimulation to oppose LPS-induced apoptosis, myometrial strips were incubated with LPS 10 μg/ml for 48 h in the presence or absence of Compound A, a selective ADRB3 agonist (Croci T et Al. J Pharmacol Exp Ther 2007; 321: 1118-1126) (0.1 μM, 1 μM, and 10 μM) added immediately prior to begin LPS stimulation. Time-matched control experiments were performed with the solvent of Compound A, i.e. distilled water containing ethanol 0.3% and DMSO 0.02% as final bath concentration, both non-stimulated and LPS-stimulated myometrial samples. - At the end of the stimulation period, the supernatants samples and tissues were quickly frozen in liquid nitrogen and stored at −80° C.
- Western Blotting Analysis
- Snap-frozen myometrial tissues were homogenized with Ultra-Turrax in homogenization buffer [10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 40 mg/ml−1 leupeptine, 2 mM Pefabloc]. After an initial centrifugation at 500×g for 15 min at 4° C., total protein supernatant content was determined by the Bradford method with BSA as standard. Samples (40 μg of protein by lane) were dissolved (vol/vol) in 2× Laemmli buffer (Laemmli U K et al. J Mol Biol 1970; 47: 69-85) and boiled for 5 min before electrophoresis on a 10% SDS-PAGE. Proteins were transferred to a nitrocellulose membrane (Hybond-P, Amersham Biosciences). In order to block non specific antibody binding, membranes were incubated for 1 h in 10% nonfat dried milk powder in Tris-buffered saline/Tween 20 (TBST) (10 mM Tris, 150 mM NaCl, and 0.1% Tween 20, pH 7.8) at room temperature. Blocked membranes were washed 3 times with TBST. The blots were then incubated overnight at 4° C. with a 1:200 dilution of primary cleaved caspase-3 antibody (ASP175, Cell Signaling Technologies, Beverly, Mass., USA) or a 1:500 dilution of primary BAX polyclonal antibody (sc-493, Santa Cruz, USA) or a 1:500 dilution of primary BCL2 polyclonal antibody (sc-7382, Santa Cruz, USA) in 1% non fat dried milk powder in PBST. After three washes with PBST, the blots were incubated for 45 min with horseradish peroxidase-conjugated antirabbit IgG (NA 934, Amersham, USA) or antimouse IgG (NA 931, Amersham, USA) whole antibody at a dilution of 1:10000 at room temperature and thereafter washed five times with PBST. Immunoreactive proteins were detected by chemiluminescence (ECL™ detection reagents, RPN2105, Amersham, USA) and exposure to a X-ray film (Hyperfilm™, Amersham Bioscience, USA). The intensities of the bands were analyzed densitometrically using the NIH Image 1.62 program and normalized with intensity of bands obtained with monoclonal antibody to Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH) used as protein loading control. Results are expressed as the mean±s.e.m. in Arbitrary Density Unit (A.D.U).
- Immunohistochemical Analysis
- The myometrial strips were fixed for 1 h with paraformaldehyde 4%, then embedded in paraffin and cut into 5-micrometer-thick sections. After deparaffinization of myometrial sections, and rehydratation, antigen retrieval was performed by incubating slides 10 min in warm citric
acid buffer pH 6 with a pressure cooker. After endogenous peroxidase activity was blocked with hydrogen peroxide (H2O2) 3%, slides were incubated either with primary anti-cleaved caspase-3 IgG (1:100), washed three times with phosphate buffered saline (PBS) and then incubated with biotinylated anti-rabbit (1:600) immunoglobulin respectively for 1 h. After a new washing, slides were incubated in peroxidase labelled streptavidin (1:800) for 30 min and then with 3-amino-9-ethyl carbazole (AEC) solution until a clearly visible color was developed. The reaction was stopped by extensive washing in double distilled water. Subsequently, the preparations were counterstained with hematoxilin. The histological changes were evaluated in term of variation of global intensity of staining. Negative controls were carried out by omitting the primary antibody. - Hoechst Staining
- To distinguish between apoptotic and necrotic cells, chromatin condensation state was assessed by staining of nuclei with Hoechst-33342. Paraffin embedded sections of myometrium samples were re-hydrated as described above. Slides were then incubated for 2 min with Hoechst-33342 (2 μg/ml). The slides were rinsed with distilled water and mounted with Aquatex©. The stained nuclei were visualized with convert fluorescent microscope at a magnification of ×100, using excitation light at 350 nm.
- Real Time Quantitative RT-PCR
- Total RNA was prepared from 5 myometrial tissues obtained from 5 different women, using Trizol solution (Life Technologies, Groningen, The Netherlands) according to the manufacturer's instructions. The integrity of RNA was verified by edithidium bromide staining of agarose gel analysis and by an optical density (OD) absorption ratio OD260 nm/OD280 nm≧1.8. One microgram of total RNA was reverse transcribed with Super script II RNAase H-reverse transcriptase (Invitrogen Life Technologies, Groningen, The Netherlands) using oligo (dT) according to the manufacturer's instruction. Real time quantitative PCR analyses were performed using 25 ng of reverse transcribed total RNA with 200 nM of both sense and anti sense primers in a final volume of 25 μl using the SYBR Green PCR jumpstart reagent (Sigma, Saint Louis, Mo., USA) in an iCycler iQ real time detection system instrument (Bio-Rad, Marnes-1a-Coquette, France). PCR products were also analyzed on edithium bromide stained agarose gel to ensure that a single amplicon of the expected size was indeed obtained.
- Each reaction was performed in duplicate and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used in each experiment to control for variability in the quantities of cDNA. Relative quantification for any given gene, expressed as fold variation over control, was calculated after determination of the difference between cycle threshold (Ct) value of the given gene according to manufacturers protocol using the
formula 2−Δ(ΔCtA-ΔCtB), in which ΔCtA is ΔCt of the gene of interest; ΔCtB is ΔCt of GAPDH. ΔCt=Ct of the experimental group—Ct of the control group. PCR was performed using specific primers: GAPDH (Forward, 5′TGCACCACCAACTGCTTAGC3′ (SEQ ID NO:1), and Reverse, 5′GGCATGGACTGTGGTC-ATGAG3′ (SEQ ID NO:2)) and CASPASE-3 (Forward, 5′AGAACTGGACTGTGGCATTGAG 3′ (SEQ ID NO:3), and Reverse, 5′GCTTGTCGGCATACTGTTTCAG 3′ (SEQ ID NO:4)). - Cytokines Level Measurement
- Cytokines measurements were determined by Cytometric Bead Array (CBA; Bender MedSystems). Supernatants of 5 myometrial strips were incubated with labeled capture beads and detection reagent for 3 h in the dark at room temperature, and analyzed with a flow cytometer (FACSCalibur; BD Biosciences) by using the respective CBA Analysis software (BD Biosciences) and Bender MedSystems software. Cytokine standards for quantification (pg/mL) as well as the blanks were handled in the same manner as the samples. Each experiment was performed in duplicate to ensure for reproducibility of results.
- Statistical Analysis of Results
- Differences among groups were determined by analysis of variance (ANOVA) followed by the Dunn's multiple comparison test. Statistical analysis was carried out using GraphPad Instat version 3 (GraphPad Software, San Diego, Calif.). All differences were considered significant when P<0.05.
- Effect of the Selective ADRB3 Agonist Compound A on Apoptosis and Inflammation
- Immunostaining of 4 myometrial tissues samples obtained from 4 different women with confirmed chorioamnionitis, using cleaved caspase-3 antibody, showed an intense staining (data not shown) that was observed neither in one control tissue obtained from a woman with postpartum hemorrhage (Sheiner E et al. J Matern Fetal Neonatal Med 2005; 18: 149-154) (data not shown) nor in 3 tissues obtained at elective cesarean delivery (data not shown). This staining was specifically located in myometrial cells. LPS stimulation in optimal conditions (i.e 10 μg/ml for 48 h, determined after time course—8 h, 24 h, 48 h—and dose response—50 ng/ml, 1 μg/ml, 10 μg/ml—experiments of LPS stimulation), was also associated with an intense cleaved caspase-3 staining specifically located in myometrial cells (data not shown).
- Hoechst-33342 staining of myometrial section obtained from women with chorioamnionitis (n=4), postpartum hemorrhage (n=1) or elective cesarean delivery stimulated (n=4) or not (n=4) with LPS, showed that chorioamnionitis and LPS stimulation (data not shown), were both associated with an increased proportion of cells with condensed chromatin, indicating apoptosis initiation, compared with postpartum hemorrhage or cesarean delivery (data not shown).
- Western blotting of membranes prepared from pregnant myometrium obtained from the same 3 women with chorioamnionitis or from 5 cesarean section and stimulated, or not (controls), with LPS, revealed a 17-kDa and a 19-kDa bands corresponding to cleaved caspase-3 (data not shown). Densitometric immunoblot analysis indicated that cleaved caspase-3 protein was significantly overexpressed both in case of chorioamnionitis and after LPS stimulation compared with elective cesarean delivery without LPS stimulation used as control (expressed in arbitrary density unit, ADU, 921±39, 941.6±134, vs 452±50.6, for chorioamnionitis, LPS 10 μg/ml and control group respectively, P<0.05) (
FIG. 1 ). The overexpression of cleaved caspase-3 induced by LPS stimulation was in the same extent as that observed in western blot experiments performed in membranes prepared from pregnant myometrium women with chorioamnionitis (FIG. 1 ) providing external validation of in vitro LPS induced model of chorioamnionitis. - This over-expression of cleaved caspase-3 was strongly antagonized by the blockade of TNF-alpha receptor with a selective TNF-alpha antibody suggesting that LPS-induced apoptosis in human near-term myometrium involves TNF-alpha signaling pathway (
FIG. 2 , ANOVA P<0.05, n=3) - Our model of inflammation was validated by the measurement of supernatant cytokines production. In our experimental conditions, LPS stimulation was associated, at 48 h, with a significant increase of IL6 (mean±sem in pg/ml 28860±5257 vs 61860±12190, for control and LPS groups respectively; n=10 experiments from 5 different women, P<0.05) and IL8 (in pg/ml 8855±1486 vs. 16080±2834, for control and LPS groups respectively; n=10 experiments from 5 different women, P<0.05) but not IL1B, IL10, IL12B or TNF levels.
This over expression of cleaved caspase-3 protein was also observed at a transcriptional level since quantitative real-time RT-PCR showed that, compared with time matched controls, incubation with 10 μg/ml LPS for 48 hours was associated with a 2.36±0.22 fold increased in transcript levels (n=3 experiments performed with myometrial tissues obtained from 3 different women). - This weak effect on caspase-3 mRNA expression might be explained by our experimental conditions, i.e. 48 hours of incubation with LPS. Indeed, in an exploratory analysis we assessed time-trend for caspase-3 mRNA expression (3, 6, 12, 48 and 72 hours) and found that the peak for mRNA expression occurred around 3 hours of stimulation (in fold increase compared with controls: 8.6, 6.1, 2.3, 2.1, 1.2 at 3 h, 6 h, 16 h, 48 h and 72 h respectively).
- In a further set of experiments, western blot experiments revealed that the selective ADRB3 agonist, Compound A, was able to significantly antagonize LPS-induced changes in cleaved caspase-3 expression in a concentration dependent manner (
FIG. 3 , ANOVA P<0.001,). Furthermore, we observed that LPS-induced activation of the mitochondrial pathway of apoptosis, as expressed by BAX and BCL2 protein up- and down-regulation, respectively, was antagonized in a concentration dependant manner (FIG. 4 , ANOVA, P<0.01). Compound A had no effect by itself on cleaved caspase-3, BAX and BCL2 expression in tissues not stimulated with LPS (data not shown). The solvent for the highest concentration of Compound A, i.e. distilled water containing ethanol 0.3% and DMSO 0.02%, had no effect on cleaved caspase-3, BAX and BCL2 expression in tissues either not stimulated or stimulated with LPS (data not shown). - The effect of Compound A on caspase-3 over-expression was, at least partially, explained at a transcriptional level since quantitative real-time RT-PCR, showed that ADRB3 treatment was associated with a decreased level of caspase-3 transcripts (in fold increase, normalized to GAPDH, compared with controls 2.08±0.63, 1.17±0.81, 0.84±0.53, 0.93±0.41, respectively for LPS alone and with Compound A 10−7, 10−6 and 10−5 M respectively, ANOVA, P<0.05).
- Finally, Compound A decreased IL6 and IL8 in a concentration dependent manner, even though the effect was statically significant only for IL8 (ANOVA P=0.01;
FIG. 5 ). Compound A had not effect by itself on IL6 and IL8 release in tissues not stimulated with LPS (data not shown). TNF was under the lower level of detection for the flow-cytometry technique at 48 hours. - Altogether, these results demonstrate that Compound A reverses an LPS-induced apoptosis and cytokines production in human near term myometrium.
- Pharmaceutical Composition According to the Invention
- As a representative example, a unitary dosage form of a compound of the invention in the form of a tablet may comprise the following constituents:
-
Compound A 50.0 mg Mannitol 223.75 mg Sodium Croscaramellose 6.0 mg Corn starch 15.0 mg Hydroxypropyl-methylcellulose 2.25 mg Magnesium stearate 3.0 mg
Claims (18)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07290845A EP2011490A1 (en) | 2007-07-05 | 2007-07-05 | Beta adrenergic receptor ligand derivatives for modulating apoptosis |
EP07290845.2 | 2007-07-05 | ||
EP07290845 | 2007-07-05 | ||
PCT/IB2008/002752 WO2009019607A2 (en) | 2007-07-05 | 2008-07-04 | Beta adrenergic receptor ligand derivatives for modulating apoptosis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/002752 Continuation WO2009019607A2 (en) | 2007-07-05 | 2008-07-04 | Beta adrenergic receptor ligand derivatives for modulating apoptosis |
Publications (2)
Publication Number | Publication Date |
---|---|
US20100311829A1 true US20100311829A1 (en) | 2010-12-09 |
US9161925B2 US9161925B2 (en) | 2015-10-20 |
Family
ID=38519604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/652,317 Expired - Fee Related US9161925B2 (en) | 2007-07-05 | 2010-01-05 | Therapeutic uses of beta-3 adrenergic receptor agonist derivatives in particular to modulate apoptosis |
Country Status (4)
Country | Link |
---|---|
US (1) | US9161925B2 (en) |
EP (2) | EP2011490A1 (en) |
JP (1) | JP5539195B2 (en) |
WO (1) | WO2009019607A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009061918A1 (en) | 2007-11-06 | 2009-05-14 | Oklahoma Medical Research Foundation | Extracellular histones as biomarkers for prognosis and molecular targets for therapy |
CN102764438A (en) * | 2012-01-30 | 2012-11-07 | 林曙光 | Novel application of beta3 adrenoceptor agonist |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2817257B1 (en) * | 2000-11-30 | 2009-03-20 | Sanofi Synthelabo | CYCLOHEXYL (ALKYL) -PROPANOLAMINES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2840301B1 (en) * | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | PHENYL-CYCLOHEXYL-PROPANOLAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS |
FR2840304B1 (en) * | 2002-05-29 | 2007-05-18 | Sanofi Synthelabo | OXOPHENYL-CYCLOHEXYL-PROPANOLAMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
-
2007
- 2007-07-05 EP EP07290845A patent/EP2011490A1/en not_active Withdrawn
-
2008
- 2008-07-04 JP JP2010514191A patent/JP5539195B2/en not_active Expired - Fee Related
- 2008-07-04 EP EP08827157A patent/EP2173335B1/en active Active
- 2008-07-04 WO PCT/IB2008/002752 patent/WO2009019607A2/en active Application Filing
-
2010
- 2010-01-05 US US12/652,317 patent/US9161925B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
Ngassa et al (Int J Gynaecol Obstet 47:241-246, 1994 (Abstract only)) * |
Perfettini et al (Infection and Immunity 68:2237-2244, 2000) * |
Also Published As
Publication number | Publication date |
---|---|
EP2011490A1 (en) | 2009-01-07 |
JP2010532342A (en) | 2010-10-07 |
WO2009019607A2 (en) | 2009-02-12 |
EP2173335A2 (en) | 2010-04-14 |
US9161925B2 (en) | 2015-10-20 |
WO2009019607A4 (en) | 2009-05-28 |
WO2009019607A3 (en) | 2009-04-09 |
EP2173335B1 (en) | 2012-09-19 |
JP5539195B2 (en) | 2014-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Oh et al. | Autophagy-related proteins, LC3 and Beclin-1, in placentas from pregnancies complicated by preeclampsia | |
US20090281110A1 (en) | Method of Treatment | |
WO2013052995A2 (en) | Improved developmental competence of oocytes | |
CA2837359C (en) | Methods and compositions for enhancing fertility and/or inhibiting pregnancy failure and restoring glucose tolerance | |
CN106796243B (en) | Judge the method for the risk of premature labor and/or infant of low-birth weight's fertility and the kit for this method | |
US9161925B2 (en) | Therapeutic uses of beta-3 adrenergic receptor agonist derivatives in particular to modulate apoptosis | |
JP2022504990A (en) | Compositions and Methods for Treating Vascular Ehlers-Danlos Syndrome and Related Disorders | |
US20220390474A1 (en) | Detection and Treatment of Conditions Related to Luteinizing Hormone/Follicle-Stimulating Hormone (LH/FSH) Levels | |
KR20140138824A (en) | Method for treating gynecological diseases | |
KR102675587B1 (en) | Pharmaceutical composition for preventing or treating diseases related to abnormal proliferation of endometrial cells or trophoblast cells comprising fenbendazole, oxibendazole or mixture thereof | |
US20160279202A1 (en) | Interleukin-1 (il-1) inhibitors for treating fertility disorders | |
JP6840775B2 (en) | Methods to reduce perinatal illness and / or mortality | |
CZ20011524A3 (en) | Use of thiazolidinediones derivatives for preventing uterine contractions in premature labor or lactation | |
KR102434351B1 (en) | Pharmaceutical composition for preventing or treating male reproductive disease comprising butylated hydroxyanisole, butylated hydroxytoluene or mixture thereof | |
US20070270392A1 (en) | Use of a Cyclopentenone Prostaglandin for Delaying the Onset and/or Preventing the Continuation of Labour | |
KR102066149B1 (en) | Composition comprising C-C motif chemokine ligand 2(CCL2) for improving pregnancy | |
US20230285347A1 (en) | Preterm Labour with Prostaglandin E2 Receptor Agonists | |
CN115590849A (en) | Oxytocin antagonist dosing regimen to promote embryo implantation and prevent miscarriage | |
US20190255025A1 (en) | Methods and compositions for enhancing fertility and/or inhibiting pregnancy failure and restoring glucose tolerance | |
Nakashima et al. | The Role of Autophagy in Maintaining Pregnancy | |
KR20220075340A (en) | Oxytocin antagonist administration regimen to promote embryo implantation and prevent miscarriage | |
WO2022200848A1 (en) | Pterostilbene for use in the treatment or prevention of infertility | |
Coughlan et al. | Polycystic ovarian syndrome | |
EP1827451A1 (en) | Use of a cyclopentenone prostaglandin for delaying for the onset and/or preventing the continuation of labour | |
Konje | Ectopic Pregnancy Is Associated with High Anandamide Levels and Aberrant Expression of FAAH and CB1 in Fallopian Tubes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANOFI-AVENTIS, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BARDOU, MARC;REEL/FRAME:024846/0169 Effective date: 20100615 |
|
AS | Assignment |
Owner name: SANOFI, FRANCE Free format text: CHANGE OF NAME;ASSIGNOR:SANOFI-AVENTIS;REEL/FRAME:028413/0927 Effective date: 20110511 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20231020 |